Eli Lilly & Co. will begin disclosing the results of all trials on the drugs it sells in an online registry it plans to have available later this year, the company announced last week.
Trial results contrary to the expected outcome of the drug will be disclosed, along with comprehensive descriptions of the methodology for each study, the Indianapolis-based firm said.
"Lilly understands that patients, customers and critics are looking for transparent answers that provide value to the healthcare decision-making process," Sidney Taurel, Eli Lilly's chairman, president and chief executive, said in a news release. "These actions should prove to be invaluable for patients and the medical community as they seek to make informed decisions about Lilly medicines."
Eli Lilly's announcement comes after the American Medical Association in June approved a resolution calling on the federal government to create a public registry for all drug study results so that unfavorable results also get attention.
GlaxoSmithKline last month announced plans for similar drug trial disclosures.
AMA Trustee Joseph Heyman, M.D., said in a statement that the organization "is encouraged by signs of support from Eli Lilly and others in the pharmaceutical industry for greater transparency in the clinical trial process, including a commitment to disclose trial results.
"Ultimately, the AMA believes a comprehensive clinical trials registry is necessary to reduce the impact of publication bias, prevent duplication of effort, promote collaboration and improve evidence-based medical practice."